0001493152-23-044790.txt : 20231214 0001493152-23-044790.hdr.sgml : 20231214 20231214081527 ACCESSION NUMBER: 0001493152-23-044790 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231214 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231214 DATE AS OF CHANGE: 20231214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Microbot Medical Inc. CENTRAL INDEX KEY: 0000883975 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 943078125 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19871 FILM NUMBER: 231485658 BUSINESS ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 BUSINESS PHONE: 908-938-5561 MAIL ADDRESS: STREET 1: 25 RECREATION PARK DR SUITE 108 CITY: HINGHAM STATE: MA ZIP: 02043 FORMER COMPANY: FORMER CONFORMED NAME: STEMCELLS INC DATE OF NAME CHANGE: 20000524 FORMER COMPANY: FORMER CONFORMED NAME: CYTOTHERAPEUTICS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 14, 2023

MICROBOT MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware

000-19871

94-3078125

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

288 Grove Street, Suite 388

Braintree, MA 02184

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		MBOT		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On December 14, 2023, Microbot Medical Inc. (the “Company”) issued a press release announcing that it has entered into a collaboration agreement with Corewell Health™ (“Corewell”). The objective of the collaboration, which will take place in multiple phases, is to enable telerobotics between remote centers by utilizing the Company’s LIBERTY^® Endovascular Robotic Surgical System. The agreement with Corewell includes the right to mutually evaluate the LIBERTY System for remote procedures, which will be led by Ryan Madder, M.D., an expert in interventional cardiology.

The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

Exhibit		Description
99.1		Press release, dated December 14, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MICROBOT MEDICAL INC.

	By:	/s/ Harel Gadot
	Name:	Harel Gadot
	Title:	Chief Executive Officer, President and Chairman

Date: December 14, 2023

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY^®Endovascular Robotic Surgical System for Telerobotic

The first phase in the collaboration will evaluate the current state of the LIBERTY^® Robotic Surgical System in connection with remote enabled Endovascular treatments.

BRAINTREE, Mass., December 14, 2023 – Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY^® Endovascular Robotic Surgical System, today announced it has entered into a collaboration agreement with Corewell Health™. The objective of the collaboration, which will take place in multiple phases, is to enable telerobotics between remote centers by utilizing the LIBERTY Endovascular Robotic Surgical System. The agreement with Corewell Health includes the right to mutually evaluate the LIBERTY System for remote procedures, which will be led by Ryan Madder, M.D., an expert in interventional cardiology.

Corewell Health is a not-for-profit health system that provides health care and coverage with a team of 60,000+ — including more than 11,500 physicians and advanced practice providers and more than 15,000 nurses, providing care and services in 21 hospitals, 300+ outpatient locations and several post-acute facilities.

“Being able to connect between remote sites, especially at rural areas, has been a passion of mine for years, and as such I’m excited about the potential this collaboration can bring to benefit many patients in the USA and across the world,” said Dr. Madder, Section Chief, Interventional Cardiology and Director, Cardiac Cath Lab at Corewell Health in Grand Rapids, Michigan.

“We are excited for the opportunity to collaborate with Corewell Health and Dr. Ryan Madder, innovators in the field of robotics and healthcare. Working together with a health system such as Corewell, which provides care and services in 21 hospitals, 300+ outpatient locations and several post-acute facilities, to enhance the telerobotic feature of the LIBERTY System, fits well with our mission to enable accessibility to any user, anywhere across the world for any endovascular procedure,” said Harel Gadot, Chairman, President and CEO. “We continue to demonstrate that the interest shown by leading medical centers in our LIBERTY System is a testament to its potential impact in the endovascular interventional space.”

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.

The LIBERTY Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY Endovascular Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures.

Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY, the outcome of its studies to evaluate LIBERTY, whether the Company’s core business focus program and cost reduction plan are sufficient to enable the Company to continue to focus on its LIBERTY technology while it stabilizes its financial condition and seeks additional working capital, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, such as employees of Microbot and its vendors and business partners being called to active military duty, any lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michal Efraty

+972-(0)52-3044404

IR@microbotmedical.com

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.LAB 4 mbot-20231214_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mbot-20231214_pre.xml XBRL PRESENTATION FILE EX-101.SCH 6 mbot-20231214.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 14, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 14, 2023
Entity File Number	000-19871
Entity Registrant Name	MICROBOT MEDICAL INC.
Entity Central Index Key	0000883975
Entity Tax Identification Number	94-3078125
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	288 Grove Street
Entity Address, Address Line Two	Suite 388
Entity Address, City or Town	Braintree
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02184
City Area Code	(781)
Local Phone Number	875-3605
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	MBOT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000883975 2023-12-14 2023-12-14 iso4217:USD shares iso4217:USD shares false 0000883975 8-K 2023-12-14 MICROBOT MEDICAL INC. DE 000-19871 94-3078125 288 Grove Street Suite 388 Braintree MA 02184 (781) 875-3605 false false false false Common Stock, $0.01 par value MBOT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://microbotmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm mbot-20231214.xsd mbot-20231214_lab.xml mbot-20231214_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "MBOT", "nsuri": "http://microbotmedical.com/20231214", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "mbot-20231214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "mbot-20231214_lab.xml" ] }, "presentationLink": { "local": [ "mbot-20231214_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://microbotmedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://microbotmedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-044790-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-044790-xbrl.zip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end